BCRX
BIOCRYST PHARMACEUTICALS INC
+0.17 (+1.96%)8.60USD1.5M成交股數2.2B市值–本益比(近四季)2.3股價營收比+33.6%營收年增(近四季)2026-11-02下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 218M+50% | 156M+19% | 159M+36% | 163M+49% | 146M+57% | 132M+52% | 117M+42% | 109M+59% | 92.8M | 86.7M | 82.5M | 68.8M |
| 營業成本 | 3.8M | 5.4M | 2.2M | 2.8M | 4.6M | 6.1M | 3.2M | 1.7M | 1.3M | 1.1M | 894K | 931K |
| 毛利 | 214M+52% | 151M+20% | 157M+38% | 161M+49% | 141M+54% | 125M+46% | 114M+40% | 108M+59% | 91.5M | 85.6M | 81.6M | 67.8M |
| 毛利率 | 98.2% | 96.6% | 98.6% | 98.3% | 96.9% | 95.4% | 97.3% | 98.4% | 98.6% | 98.7% | 98.9% | 98.6% |
| 研發費用 | 52.0M | 60.3M | 44.6M | 43.4M | 37.3M | 49.4M | 41.1M | 37.6M | 46.5M | 46.9M | 51.2M | 48.4M |
| 銷售管理費用 | 64.0M | 94.6M | 83.0M | 87.4M | 82.5M | 80.5M | 65.1M | 61.2M | 59.5M | 50.6M | 51.0M | 47.9M |
| 營業利益 | 98.5M+364% | −702M+15463% | 29.6M+285% | 29.8M+240% | 21.2M-247% | −4.5M-62% | 7.7M-137% | 8.8M-131% | −14.5M | −11.9M | −20.7M | −28.4M |
| 營業利益率 | 45.1% | -448.6% | 18.6% | 18.2% | 14.6% | -3.4% | 6.6% | 8.0% | -15.6% | -13.7% | -25.1% | -41.3% |
| 稅後淨利 | 78.4M+244884% | −722M+2594% | 12.9M-192% | 5.1M-140% | 32K-100% | −26.8M-26% | −14.0M-81% | −12.7M-76% | −35.4M | −36.1M | −75.3M | −53.3M |
| 淨利率 | 35.9% | -461.5% | 8.1% | 3.1% | 0.0% | -20.4% | -12.0% | -11.6% | -38.1% | -41.7% | -91.3% | -77.5% |
| 稀釋 EPS | 0.30 | -2.98+2192% | 0.06-186% | 0.02-133% | 0.00-100% | -0.13-32% | -0.07-83% | -0.06-79% | -0.17 | -0.19 | -0.40 | -0.28 |
| 稀釋股數 | 265M | 242M | 220M | 220M | 215M | 207M | 207M | 206M | 206M | 190M | 189M | 189M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 155M | 172M | 84.1M | 88.0M | 105M | 105M | 96.8M | 78.4M | 84.3M | 151M | 146M | 155M |
| 應收帳款 | 111M | 109M | 91.3M | 91.2M | 93.4M | 79.1M | 72.5M | 68.8M | 60.6M | 53.6M | 57.7M | 48.6M |
| 存貨 | 6.1M | 6.0M | 5.2M | 5.0M | 6.9M | 8.1M | 7.6M | 4.5M | 29.8M | 29.6M | 27.0M | 27.5M |
| 總資產 | 558M | 465M | 446M | 457M | 480M | 490M | 491M | 472M | 468M | 523M | 530M | 510M |
| 有息負債 | 395M | 395M | 194M | 243M | 315M | 315M | 314M | 314M | 308M | 298M | 293M | 233M |
| 總負債 | 1.0B | 1.0B | 834M | 879M | 932M | 966M | 960M | – | – | – | – | – |
| 股東權益 | −454M | −554M | −388M | −422M | −452M | −476M | −469M | −476M | −476M | −411M | −389M | −328M |
| 負債比 | 181.4% | 219.1% | 186.9% | 192.2% | 194.1% | 197.0% | 195.4% | – | – | – | – | – |
| 淨現金(現金 − 有息負債) | −240M | −224M | −110M | −155M | −210M | −210M | −217M | −235M | −224M | −147M | −147M | −77.4M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −61.8M | – | – | −27.5M-49% | – | – | – | −53.7M | – | – | −47.5M |
| 資本支出 | – | 403K | – | – | 143K | – | – | – | 235K | – | – | 160K |
| 自由現金流 | – | −62.2M | – | – | −27.7M-49% | – | – | – | −53.9M | – | – | −47.7M |
| 折舊攤銷 | – | – | – | – | 331K | – | – | – | 306K | – | – | 405K |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -39.8% | – | – | -19.0% | – | – | – | -58.1% | – | – | -69.3% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 875M
| Reportable | 875M | 100.0% | +94.1% |
|---|
產品／服務2025 年度 · 883M
| ORLADEYO | 602M | 68.2% | +37.5% |
|---|---|---|---|
| License | 244M | 27.6% | – |
| Other Income From Contract With Customer | 29.0M | 3.3% | +122.3% |
| Collaborative And Other Research And Development | 7.7M | 0.9% | -4.2% |
| 產品 小計 | 623M | 70.6% | +40.8% |
| License And Other Revenues 小計 | 252M | 28.5% | +3028.9% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 875M | +94.1% | 264M | 30.2% | 1.21 | 345M |
| FY2024 | 451M | +36.0% | −88.9M | -19.7% | -0.43 | −53.1M |
| FY2023 | 331M | +22.4% | −227M | -68.4% | -1.18 | −97.3M |
| FY2022 | 271M | +72.3% | −247M | -91.2% | -1.33 | −163M |
| FY2021 | 157M | +782.4% | −184M | -117.1% | -1.03 | −145M |
| FY2020 | 17.8M | -63.5% | −183M | -1,026.4% | -1.09 | −136M |
| FY2019 | 48.8M | +136.5% | −109M | -223.0% | -940.00 | −89.9M |
| FY2018 | 20.7M | – | −101M | -490.3% | -0.98 | −92.9M |